Odyssey Therapeutics, Inc.

S-1 filed

Odyssey Therapeutics, Inc. is conducting an initial public offering (IPO) of its common stock, aiming to raise capital to advance its pipeline of small-molecule and protein therapeutic candidates targeting autoimmune and inflammatory diseases. The company's lead program, OD-001, has demonstrated proof-of-concept in a phase 2a trial for ulcerative colitis, while OD-002 is in IND-enabling studies. The IPO is contingent on listing on Nasdaq under the symbol 'ODTX', with underwriters including J.P. Morgan and TD Cowen. The filing emphasizes its focus on innate immune system targets to address limitations of existing therapies.

DRS/A amended

Odyssey Therapeutics, Inc. is preparing for its initial public offering (IPO) of common stock, aiming to raise capital to advance its clinical-stage biopharmaceutical programs targeting autoimmune and inflammatory diseases. The company's lead candidates, OD-001 and OD-002, are in phase 2a and IND-enabling studies, respectively, with OD-001 demonstrating proof-of-concept in ulcerative colitis. The filing outlines plans to list on Nasdaq under the symbol 'ODTX,' contingent on regulatory approvals and market conditions.

DRS/A amended

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune and inflammatory diseases. The company is conducting an initial public offering (IPO) of its common stock, with an estimated price range and plans to list on Nasdaq under the symbol 'ODTX.' Key programs include OD-001 (phase 2a for ulcerative colitis) and OD-002 (preclinical SLC15A4 inhibitor). The filing highlights its expertise in immunobiology, small-molecule drug discovery, and collaborations with partners like Terray Therapeutics.

DRS filed

Odyssey Therapeutics, Inc. has submitted a confidential DRS filing for an upcoming IPO, aiming to offer shares of its common stock with an estimated price range. The company plans to list on Nasdaq under 'ODTX' and is an emerging growth company. Financial statements for 2023 and 2025 are omitted but will be included in a future amendment. The offering is contingent on Nasdaq approval, with underwriters having an option to purchase additional shares.

RW withdrawn

Odyssey Therapeutics, Inc. has withdrawn its previously filed S-1 registration statement for an initial public offering (IPO). The company cited that proceeding with the offering is no longer in its best interest, though the registration was never effective and no securities were issued. The withdrawal request includes a fee credit for SEC filings and return of supplemental materials. The company remains a clinical-stage biopharmaceutical firm focused on autoimmune and inflammatory diseases.

S-1 filed

Odyssey Therapeutics, Inc. is conducting an initial public offering (IPO) for its common stock, aiming to list on Nasdaq under the symbol ODTX. The company, a clinical-stage biopharmaceutical firm, focuses on developing therapies targeting autoimmune and inflammatory diseases by modulating the innate immune system. Key programs include OD-07656 for ulcerative colitis and preclinical candidates targeting IRAK4 and TNFR2. The IPO follows a confidential DRS/A filing, with updated details on clinical trial timelines and underwriting arrangements.

DRS/A amended

Odyssey Therapeutics, Inc. is conducting an initial public offering (IPO) of its common stock, aiming to raise capital to advance its clinical-stage biopharmaceutical programs targeting autoimmune and inflammatory diseases. The company focuses on developing precision medicines targeting the innate immune system, with key candidates including OD-07656 (RIPK2 inhibitor) and preclinical programs like IRAK4 and OD-00910. The IPO includes planned Phase 2a trials for ulcerative colitis and combination therapies, with underwriters including Goldman Sachs, Jefferies, TD Cowen, and Wedbush PacGrow. The offering is contingent on Nasdaq listing and regulatory approvals.

DRS/A amended

Odyssey Therapeutics, Inc. is conducting an initial public offering (IPO) of its common stock, aiming to raise capital to advance its clinical-stage biopharmaceutical programs targeting autoimmune and inflammatory diseases. The company focuses on modulating the innate immune system through small molecule and protein therapeutics, with key candidates including OD-07656 (RIPK2 inhibitor) and preclinical programs targeting IRAK4 and TNFR2. The IPO is contingent on Nasdaq listing approval, and the company has not yet established a public market for its shares.

DRS filed

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune and inflammatory diseases by targeting the innate immune system. The company is conducting an initial public offering (IPO) of its common stock, with an estimated price range and planned listing on the Nasdaq Capital Market under the ticker symbol ODTX. The filing includes details on its lead candidates, including OD-07656 for ulcerative colitis, and preclinical programs targeting IRAK4 and TNFR2. The company is classified as an emerging growth company and smaller reporting company, with underwriters including Goldman Sachs, Jefferies, TD Cowen, and Wedbush PacGrow.